Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Free Report) was the recipient of a large increase in short interest in October. As of October 15th, there was short interest totalling 1,170,000 shares, an increase of 1,274.9% from the September 30th total of 85,100 shares. Based on an average trading volume of 2,890,000 shares, the days-to-cover ratio is presently 0.4 days. Approximately 38.2% of the company’s stock are short sold.
Bright Minds Biosciences Stock Performance
Bright Minds Biosciences stock traded down $0.56 during mid-day trading on Friday, reaching $48.94. The company’s stock had a trading volume of 946,421 shares, compared to its average volume of 934,862. Bright Minds Biosciences has a 12-month low of $0.93 and a 12-month high of $79.02. The firm’s fifty day moving average price is $8.51 and its two-hundred day moving average price is $3.67. The company has a market capitalization of $217.00 million, a P/E ratio of -48.46 and a beta of 1.56.
Bright Minds Biosciences (NASDAQ:DRUG – Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported $0.04 EPS for the quarter.
Insider Transactions at Bright Minds Biosciences
Bright Minds Biosciences Company Profile
Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.
Featured Stories
- Five stocks we like better than Bright Minds Biosciences
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Earnings Per Share Calculator: How to Calculate EPS
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.